Global analytical strategy to measure drug-plasma protein interactions : from high-throughput to in-depth analysis
Copyright © 2013 Elsevier Ltd. All rights reserved..
The selection of drug candidates with improved pharmacokinetics is essential to reduce the attrition rates during drug development and represents one of the big challenges faced by the pharmaceutical industry. Plasma protein binding (PPB) is an important parameter with significant implications for in vivo drug performance. Today, the most widely used techniques for PPB measurement in the pharmaceutical community are equilibrium dialysis (ED) and ultrafiltration (UF). However, these techniques have some limitations. Thus, we emphasize an alternative strategy, based on a global, new and easy-to-follow methodology, to screen and perform determination of PPB, using orthogonal techniques (i.e. liquid chromatography (LC), capillary electrophoresis (CE), surface plasmon resonance (SPR) based biosensor). We anticipate that the increased knowledge gained through this strategy will lead to improved drug candidates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Drug discovery today - 18(2013), 21-22 vom: 02. Nov., Seite 1030-4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vuignier, Karine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.04.2014 Date Revised 11.11.2013 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drudis.2013.04.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM226846520 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM226846520 | ||
| 003 | DE-627 | ||
| 005 | 20231224072339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2013.04.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0756.xml |
| 035 | |a (DE-627)NLM226846520 | ||
| 035 | |a (NLM)23603634 | ||
| 035 | |a (PII)S1359-6446(13)00100-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vuignier, Karine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Global analytical strategy to measure drug-plasma protein interactions |b from high-throughput to in-depth analysis |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2014 | ||
| 500 | |a Date Revised 11.11.2013 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Elsevier Ltd. All rights reserved. | ||
| 520 | |a The selection of drug candidates with improved pharmacokinetics is essential to reduce the attrition rates during drug development and represents one of the big challenges faced by the pharmaceutical industry. Plasma protein binding (PPB) is an important parameter with significant implications for in vivo drug performance. Today, the most widely used techniques for PPB measurement in the pharmaceutical community are equilibrium dialysis (ED) and ultrafiltration (UF). However, these techniques have some limitations. Thus, we emphasize an alternative strategy, based on a global, new and easy-to-follow methodology, to screen and perform determination of PPB, using orthogonal techniques (i.e. liquid chromatography (LC), capillary electrophoresis (CE), surface plasmon resonance (SPR) based biosensor). We anticipate that the increased knowledge gained through this strategy will lead to improved drug candidates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Blood Proteins |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Veuthey, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Carrupt, Pierre-Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Schappler, Julie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discovery today |d 1998 |g 18(2013), 21-22 vom: 02. Nov., Seite 1030-4 |w (DE-627)NLM095449159 |x 1878-5832 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2013 |g number:21-22 |g day:02 |g month:11 |g pages:1030-4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drudis.2013.04.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2013 |e 21-22 |b 02 |c 11 |h 1030-4 | ||